NON-INTERVENTIONAL STUDY TO REVIEW THE CHANGES OF DEPRESSION AFTER FIRST-YEAR OF TOFACITINIB TREATMENT IN RHEUMATOID ARTHRITIS (XELJANZ (Registered))
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Mar 2024 Status changed from active, no longer recruiting to completed.
- 07 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2021 Planned End Date changed from 31 May 2023 to 22 Jan 2024.